SecBot SecBot
PRESS-RELEASE ·Filed Jun 4, 2026

NRXP

NRx Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The dilutive offering at a 2.8% discount to the current price (assuming $3.60 close) adds overhang. Monitor for further dilution if the shelf is tapped again. The company's cash runway extends but at the cost of shareholder value.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.14
T+0 close · Jun 4, 2026 · via day close
Latest settled
−15.94%
T+60 · $3.48
Vs SPY
−19.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $4.14entry
  2. T+1 · 5mo ago +4.59%α +4.36% · $4.33
  3. T+5 · 5mo ago −7.25%α −7.82% · $3.84
  4. T+20 · 4mo ago −4.71%α −6.57% · $3.95
  5. T+60 · 3mo ago −15.94%α −19.94% · $3.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds. The proceeds will be used for working capital and general corporate purposes to support the company's clinical-stage pipeline for CNS disorders.

Key Financial Metrics

Deal Value
$22.3M

Key Facts

  • Closed underwritten public offering of common stock at $3.50 per share
  • Gross proceeds of approximately $22.3 million
  • Proceeds to be used for working capital and general corporate purposes
  • BTIG and Lucid Capital Markets acted as bookrunners
  • Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)

Financial Impact

Dilution of approximately 6.37 million shares at $3.50 per share, representing about 15% of pre-offering shares outstanding (based on $147M market cap / $3.50 = 42M shares pre-offering). Gross proceeds of $22.3 million.

dilutioncash

Risk Factors

  • Further dilution from remaining shelf capacity
  • Clinical-stage pipeline with no approved products; regulatory and commercial risks
  • Potential for additional capital raises given operating losses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3307137

Track record

22 reports on NRXP

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026